Regulatory Reliance and Worksharing: A Practical Guide for Faster Global Market Access
Regulatory reliance and worksharing: a practical guide for faster global accessRegulatory authorities around the world are increasingly using reliance and worksharing mechanisms to reduce duplicated effort, speed reviews, and improve access to new medicines and devices. For regulatory affairs teams, understanding how these pathways work and how to prepare submissions that meet multiple authorities’ expectations is now a core competency.
What reliance and worksharing mean
Reliance describes a regulator’s formal decision to consider assessments, inspections, or decisions performed by another trusted authority when making its own regulatory decision. Worksharing goes further by enabling multiple authorities to jointly assess a dossier or coordinate inspections and questions. Both approaches rest on trust, transparency, and robust documentation.
Why this matters to sponsors
Using reliance and worksharing can shorten review timelines, reduce the need for repetitive resources, and lower the administrative burden of separate national reviews. It can also facilitate more predictable market entry strategies and align post-approval monitoring across jurisdictions. That said, reliance is not a one-size-fits-all shortcut: national legal frameworks, labeling conventions, and market access conditions often still require tailored actions.
Practical steps for a successful reliance strategy
– Map target markets and identify reliance mechanisms: Start by listing markets where reliance or mutual recognition is available. Look for regional initiatives, collaborative review programs, and WHO collaborative procedures. Prioritize jurisdictions where reliance provides the clearest pathway to market access.
– Build a harmonized dossier: Prepare a core dossier that aligns with international standards and is adaptable to local requirements. Maintain modular documents and cross-references so country-specific modules or labeling can be added without reworking the whole submission.
– Invest in regulatory intelligence: Track participating authorities’ guidance, reliance agreements, and precedent decisions. Intelligence helps anticipate questions and ensures submission content follows the expectations of the reference authority.
– Prepare high-quality assessment and inspection packages: Authorities relying on another’s assessment expect clear, complete documentation.
Include inspection reports, manufacturing data, risk assessments, and comprehensive clinical evidence packages.
– Plan for local requirements: Even when a review relies on another authority’s assessment, countries may require local clinical data, stability studies, or specific labeling elements.
Prepare bridging documents and rationale for extrapolations.
– Engage early and transparently: Request pre-submission meetings or scientific advice where available. Early alignment with regulators reduces surprises and builds confidence in reliance pathways.
– Strengthen post-market surveillance: Collaborative review works best when robust safety monitoring and product vigilance are in place. Implement harmonized PMS plans and be ready to share real-world data with authorities cooperating on reliance.
Risks and mitigation
Regulatory reliance can expose a product to differing interpretations of benefit-risk or to national legal constraints. Mitigate these risks by validating the reference authority’s practices, maintaining local regulatory representation, and keeping flexible commercialization plans that accommodate country-specific conditions.
Operational enablers
Adopt standardized submission formats, maintain centralized regulatory tracking, and leverage electronic submission gateways where available. Training cross-functional teams on reliance concepts—clinical, quality, legal, and commercial—ensures coordinated responses during joint assessments.
A strategic opportunity
Reliance and worksharing are reshaping how products move through regulatory systems. For companies that plan strategically, invest in dossier quality, and engage proactively with regulators, these mechanisms offer a pathway to faster, more efficient global access while maintaining compliance and patient safety. Embracing this collaborative mindset positions regulatory affairs teams to deliver both speed and confidence across diverse markets.